The pharmaceutical sector is a cornerstone of global healthcare, with immense growth potential, especially in the U.S. market. Indian pharma companies play a pivotal role, accounting for around 40% of generic drug supply and over-the-counter medicines in the U.S. The increasing demand for innovative treatments has fueled exports of diabetes, heart, and blood clot medications.
Additionally, India’s reputation as the “vaccine capital of the world” strengthens its global standing, producing 60% of the world’s vaccines. Rising healthcare spending, an aging population, and a surge in chronic diseases drive sustained growth in the U.S. market.
Pharma stocks, therefore, offer robust opportunities for investors, benefiting from innovation, cost efficiency, and expanding regulatory approvals in key therapeutic segments.
Share Price
The shares of Gland Pharma are currently trading at Rs. 1,810 u by 2% from its previous close of Rs. 1,775.3 as of December 12, 2024. The stock also touched an intraday high of Rs. 1,864.
Recent Update
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Phytonadione Injectable Emulsion USP, 10 mg/mL single-dose ampules.
This product, a generic version of Vitamin K1 Injectable Emulsion USP by Hospira Inc., is bioequivalent and therapeutically equivalent to the reference-listed drug. The injectable is primarily indicated for coagulation disorders (blood clots) caused by vitamin K deficiency or interference with vitamin K activity.
The company announced its plans to launch the product in the U.S. market through its marketing partners shortly.
According to IQVIA, this drug had U.S. sales of approximately $15 million for the twelve months ending September 2024, underlining its significance in the treatment of blood clot-related conditions.
With this approval, Gland Pharma continues to strengthen its portfolio in the generic injectables market, further solidifying its presence in the U.S. This development demonstrates the company’s commitment to addressing critical healthcare needs globally.
About the Company
Founded in 1978 in Hyderabad, Gland Pharma has evolved from a small-scale contract manufacturer into one of the largest injectable-focused pharmaceutical companies globally. With
a strong presence across 60 countries, including the United States, Europe, Canada, and India, the company operates under a business-to-business (B2B) model. Gland Pharma boasts an exceptional track record in the development, manufacturing, and marketing of sterile injectables, maintaining high standards of quality and innovation.
The company offers an extensive portfolio, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. A pioneer of Heparin technology in India, Gland Pharma continues to strengthen its position as a reliable partner in global healthcare by addressing critical medical needs through advanced injectable solutions.
Conclusion
Gland Pharma’s recent USFDA approval exemplifies the company’s continuous growth and strategic market positioning. By securing approvals for critical medications and maintaining a robust portfolio of sterile injectables, the company demonstrates its ability to meet global healthcare needs.
The stock’s positive market response reflects investor confidence in Gland Pharma’s potential. As healthcare demands evolve, the company’s innovative approach and extensive international footprint suggest a promising trajectory in the competitive pharmaceutical landscape.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
